Endocrine-Related Cancer

References

1. ↵
   1. Abraham RT &
   2. Gibbons JJ

   2007 The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clinical Cancer Research 13 3109–3114doi:10.1158/1078-0432.CCR-06-2798.
2. ↵
   1. Bauer DE,
   2. Hatzivassiliou G,
   3. Zhao F,
   4. Andreadis C &
   5. Thompson CB

   2005 ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24 6314–6322doi:10.1038/sj.onc.1208773.
3. ↵
   1. Bensaad K,
   2. Tsuruta A,
   3. Selak MA,
   4. Vidal MN,
   5. Nakano K,
   6. Bartrons R,
   7. Gottlieb E &
   8. Vousden KH

   2006 TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126 107–120doi:10.1016/j.cell.2006.05.036.
4. ↵
   1. Bensaad K,
   2. Cheung EC &
   3. Vousden KH

   2009 Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO Journal 28 3015–3026doi:10.1038/emboj.2009.242.
5. ↵
   1. Berwick DC,
   2. Hers I,
   3. Heesom KJ,
   4. Moule SK &
   5. Tavare JM

   2002 The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. Journal of Biological Chemistry 277 33895–33900doi:10.1074/jbc.M204681200.
6. ↵
   1. Bissler JJ,
   2. McCormack FX,
   3. Young LR,
   4. Elwing JM,
   5. Chuck G,
   6. Leonard JM,
   7. Schmithorst VJ,
   8. Laor T,
   9. Brody AS,
   10. Bean J
   11. et al.

   2008 Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New England Journal of Medicine 358 140–151doi:10.1056/NEJMoa063564.
7. ↵
   1. Bonnet S,
   2. Archer SL,
   3. Allalunis-Turner J,
   4. Haromy A,
   5. Beaulieu C,
   6. Thompson R,
   7. Lee CT,
   8. Lopaschuk GD,
   9. Puttagunta L,
   10. Harry G
   11. et al.

   2007 A mitochondria-K⁺ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11 37–51doi:10.1016/j.ccr.2006.10.020.
8. ↵
   1. Boren J,
   2. Cascante M,
   3. Marin S,
   4. Comin-Anduix B,
   5. Centelles JJ,
   6. Lim S,
   7. Bassilian S,
   8. Ahmed S,
   9. Lee WN &
   10. Boros LG

   2001 Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. Journal of Biological Chemistry 276 37747–37753doi:10.1074/jbc.M105796200.
9. ↵
   1. Boughattas NA,
   2. Levi F,
   3. Fournier C,
   4. Lemaigre G,
   5. Roulon A,
   6. Hecquet B,
   7. Mathe G &
   8. Reinberg A

   1989 Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. Cancer Research 49 3362–3368.
10. ↵
    1. Brachmann SM,
    2. Hofmann I,
    3. Schnell C,
    4. Fritsch C,
    5. Wee S,
    6. Lane H,
    7. Wang S,
    8. Garcia-Echeverria C &
    9. Maira SM

    2009 Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. PNAS 106 22299–22304doi:10.1073/pnas.0905152106.
11. ↵
    1. Brugarolas JB,
    2. Vazquez F,
    3. Reddy A,
    4. Sellers WR &
    5. Kaelin WG Jr.

    2003 TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 147–158doi:10.1016/S1535-6108(03)00187-9.
12. ↵
    1. Bruick RK &
    2. McKnight SL

    2001 A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 1337–1340doi:10.1126/science.1066373.
13. ↵
    1. Brunelle JK,
    2. Santore MT,
    3. Budinger GR,
    4. Tang Y,
    5. Barrett TA,
    6. Zong WX,
    7. Kandel E,
    8. Keith B,
    9. Simon MC,
    10. Thompson CB
    11. et al.

    2004 c-Myc sensitization to oxygen deprivation-induced cell death is dependent on Bax/Bak, but is independent of p53 and hypoxia-inducible factor-1. Journal of Biological Chemistry 279 4305–4312doi:10.1074/jbc.M312241200.
14. ↵
    1. Buzzai M,
    2. Bauer DE,
    3. Jones RG,
    4. Deberardinis RJ,
    5. Hatzivassiliou G,
    6. Elstrom RL &
    7. Thompson CB

    2005 The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24 4165–4173doi:10.1038/sj.onc.1208622.
15. ↵
    1. Carpten JD,
    2. Faber AL,
    3. Horn C,
    4. Donoho GP,
    5. Briggs SL,
    6. Robbins CM,
    7. Hostetter G,
    8. Boguslawski S,
    9. Moses TY,
    10. Savage S
    11. et al.

    2007 A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 439–444doi:10.1038/nature05933.
16. ↵
    1. Chajes V,
    2. Cambot M,
    3. Moreau K,
    4. Lenoir GM &
    5. Joulin V

    2006 Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Research 66 5287–5294doi:10.1158/0008-5472.CAN-05-1489.
17. ↵
    1. Chen EI,
    2. Hewel J,
    3. Krueger JS,
    4. Tiraby C,
    5. Weber MR,
    6. Kralli A,
    7. Becker K,
    8. Yates JR III. &
    9. Felding-Habermann B

    2007a Adaptation of energy metabolism in breast cancer brain metastases. Cancer Research 67 1472–1486doi:10.1158/0008-5472.CAN-06-3137.
18. ↵
    1. Chen Z,
    2. Odstrcil EA,
    3. Tu BP &
    4. McKnight SL

    2007b Restriction of DNA replication to the reductive phase of the metabolic cycle protects genome integrity. Science 316 1916–1919doi:10.1126/science.1140958.
19. ↵
    1. Chen CC,
    2. Jeon SM,
    3. Bhaskar PT,
    4. Nogueira V,
    5. Sundararajan D,
    6. Tonic I,
    7. Park Y &
    8. Hay N

    2010 FoxOs inhibit mTORC1 and activate akt by inducing the expression of sestrin3 and rictor. Developmental Cell 18 592–604doi:10.1016/j.devcel.2010.03.008.
20. ↵
    1. Christofk HR,
    2. Vander Heiden MG,
    3. Harris MH,
    4. Ramanathan A,
    5. Gerszten RE,
    6. Wei R,
    7. Fleming MD,
    8. Schreiber SL &
    9. Cantley LC

    2008a The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 230–233doi:10.1038/nature06734.
21. ↵
    1. Christofk HR,
    2. Vander Heiden MG,
    3. Wu N,
    4. Asara JM &
    5. Cantley LC

    2008b Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452 181–186doi:10.1038/nature06667.
22. ↵
    1. Chung S,
    2. Arrell DK,
    3. Faustino RS,
    4. Terzic A &
    5. Dzeja PP

    2010 Glycolytic network restructuring integral to the energetics of embryonic stem cell cardiac differentiation. Journal of Molecular and Cellular Cardiology 48 725–734doi:10.1016/j.yjmcc.2009.12.014.
23. ↵
    1. Clower CV,
    2. Chatterjee D,
    3. Wang Z,
    4. Cantley LC,
    5. Vander Heiden MG &
    6. Krainer AR

    2010 The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. PNAS 107 1894–1899doi:10.1073/pnas.0914845107.
24. ↵
    1. Dang CV,
    2. O'Donnell KA,
    3. Zeller KI,
    4. Nguyen T,
    5. Osthus RC &
    6. Li F

    2006 The c-Myc target gene network. Seminars in Cancer Biology 16 253–264doi:10.1016/j.semcancer.2006.07.014.
25. ↵
    1. Dang L,
    2. White DW,
    3. Gross S,
    4. Bennett BD,
    5. Bittinger MA,
    6. Driggers EM,
    7. Fantin VR,
    8. Jang HG,
    9. Jin S,
    10. Keenan MC
    11. et al.

    2009 Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462 739–744doi:10.1038/nature08617.
26. ↵
    1. David CJ,
    2. Chen M,
    3. Assanah M,
    4. Canoll P &
    5. Manley JL

    2010 HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463 364–368doi:10.1038/nature08697.
27. ↵
    1. Davies SP,
    2. Sim AT &
    3. Hardie DG

    1990 Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. European Journal of Biochemistry 187 183–190doi:10.1111/j.1432-1033.1990.tb15293.x.
28. ↵
    1. DeBerardinis RJ,
    2. Lum JJ &
    3. Thompson CB

    2006 Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth. Journal of Biological Chemistry 281 37372–37380doi:10.1074/jbc.M608372200.
29. ↵
    1. DeBerardinis RJ,
    2. Mancuso A,
    3. Daikhin E,
    4. Nissim I,
    5. Yudkoff M,
    6. Wehrli S &
    7. Thompson CB

    2007 Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. PNAS 104 19345–19350doi:10.1073/pnas.0709747104.
30. ↵
    1. Eaton S,
    2. Bartlett K &
    3. Pourfarzam M

    1996 Mammalian mitochondrial beta-oxidation. Biochemical Journal 320 345–357.
31. ↵
    1. Eberle D,
    2. Hegarty B,
    3. Bossard P,
    4. Ferre P &
    5. Foufelle F

    2004 SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86 839–848doi:10.1016/j.biochi.2004.09.018.
32. ↵
    1. Egler V,
    2. Korur S,
    3. Failly M,
    4. Boulay JL,
    5. Imber R,
    6. Lino MM &
    7. Merlo A

    2008 Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clinical Cancer Research 14 3132–3140doi:10.1158/1078-0432.CCR-07-4182.
33. ↵
    1. Epstein AC,
    2. Gleadle JM,
    3. McNeill LA,
    4. Hewitson KS,
    5. O'Rourke J,
    6. Mole DR,
    7. Mukherji M,
    8. Metzen E,
    9. Wilson MI,
    10. Dhanda A
    11. et al.

    2001 C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 43–54doi:10.1016/S0092-8674(01)00507-4.
34. ↵
    1. Evans JM,
    2. Donnelly LA,
    3. Emslie-Smith AM,
    4. Alessi DR &
    5. Morris AD

    2005 Metformin and reduced risk of cancer in diabetic patients. BMJ 330 1304–1305doi:10.1136/bmj.38415.708634.F7.
35. ↵
    1. Fan Y,
    2. Dickman KG &
    3. Zong WX

    2010 Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. Journal of Biological Chemistry 285 7324–7333doi:10.1074/jbc.M109.035584.
36. ↵
    1. Fu L,
    2. Pelicano H,
    3. Liu J,
    4. Huang P &
    5. Lee C

    2002 The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111 41–50doi:10.1016/S0092-8674(02)00961-3.
37. ↵
    1. Gao P,
    2. Tchernyshyov I,
    3. Chang TC,
    4. Lee YS,
    5. Kita K,
    6. Ochi T,
    7. Zeller KI,
    8. De Marzo AM,
    9. Van Eyk JE,
    10. Mendell JT
    11. et al.

    2009 c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458 762–765doi:10.1038/nature07823.
38. ↵
    1. Gery S,
    2. Komatsu N,
    3. Baldjyan L,
    4. Yu A,
    5. Koo D &
    6. Koeffler HP

    2006 The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Molecular Cell 22 375–382doi:10.1016/j.molcel.2006.03.038.
39. ↵
    1. Gery S,
    2. Komatsu N,
    3. Kawamata N,
    4. Miller CW,
    5. Desmond J,
    6. Virk RK,
    7. Marchevsky A,
    8. McKenna R,
    9. Taguchi H &
    10. Koeffler HP

    2007a Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clinical Cancer Research 13 1399–1404doi:10.1158/1078-0432.CCR-06-1730.
40. ↵
    1. Gery S,
    2. Virk RK,
    3. Chumakov K,
    4. Yu A &
    5. Koeffler HP

    2007b The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 26 7916–7920doi:10.1038/sj.onc.1210585.
41. ↵
    1. Gorbacheva VY,
    2. Kondratov RV,
    3. Zhang R,
    4. Cherukuri S,
    5. Gudkov AV,
    6. Takahashi JS &
    7. Antoch MP

    2005 Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. PNAS 102 3407–3412doi:10.1073/pnas.0409897102.
42. ↵
    1. Gottlob K,
    2. Majewski N,
    3. Kennedy S,
    4. Kandel E,
    5. Robey RB &
    6. Hay N

    2001 Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes and Development 15 1406–1418doi:10.1101/gad.889901.
43. ↵
    1. Gottschalk S,
    2. Anderson N,
    3. Hainz C,
    4. Eckhardt SG &
    5. Serkova NJ

    2004 Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR–ABL-positive cells. Clinical Cancer Research 10 6661–6668doi:10.1158/1078-0432.CCR-04-0039.
44. ↵
    1. Gross S,
    2. Cairns RA,
    3. Minden MD,
    4. Driggers EM,
    5. Bittinger MA,
    6. Jang HG,
    7. Sasaki M,
    8. Jin S,
    9. Schenkein DP,
    10. Su SM
    11. et al.

    2010 Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. Journal of Experimental Medicine 207 339–344doi:10.1084/jem.20092506.
45. ↵
    1. Guo D,
    2. Prins RM,
    3. Dang J,
    4. Kuga D,
    5. Iwanami A,
    6. Soto H,
    7. Lin KY,
    8. Huang TT,
    9. Akhavan D,
    10. Hock MB
    11. et al.

    2009 EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science Signaling 2 ra82doi:10.1126/scisignal.2000446.
46. ↵
    1. Gwinn DM,
    2. Shackelford DB,
    3. Egan DF,
    4. Mihaylova MM,
    5. Mery A,
    6. Vasquez DS,
    7. Turk BE &
    8. Shaw RJ

    2008 AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular Cell 30 214–226doi:10.1016/j.molcel.2008.03.003.
47. ↵
    1. Hao HX,
    2. Khalimonchuk O,
    3. Schraders M,
    4. Dephoure N,
    5. Bayley JP,
    6. Kunst H,
    7. Devilee P,
    8. Cremers CW,
    9. Schiffman JD,
    10. Bentz BG
    11. et al.

    2009 SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325 1139–1142doi:10.1126/science.1175689.
48. ↵
    1. Hatzivassiliou G,
    2. Zhao F,
    3. Bauer DE,
    4. Andreadis C,
    5. Shaw AN,
    6. Dhanak D,
    7. Hingorani SR,
    8. Tuveson DA &
    9. Thompson CB

    2005 ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8 311–321doi:10.1016/j.ccr.2005.09.008.
49. ↵
    1. Haus E,
    2. Halberg F,
    3. Pauly JE,
    4. Cardoso S,
    5. Kuhl JF,
    6. Sothern RB,
    7. Shiotsuka RN &
    8. Hwang DS

    1972 Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system. Science 177 80–82doi:10.1126/science.177.4043.80.
50. ↵
    1. He X,
    2. Ee PL,
    3. Coon JS &
    4. Beck WT

    2004 Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clinical Cancer Research 10 4652–4660doi:10.1158/1078-0432.CCR-03-0439.
51. ↵
    1. Hernlund E,
    2. Ihrlund LS,
    3. Khan O,
    4. Ates YO,
    5. Linder S,
    6. Panaretakis T &
    7. Shoshan MC

    2008 Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. International Journal of Cancer 123 476–483doi:10.1002/ijc.23525.
52. ↵
    1. Holubarsch CJ,
    2. Rohrbach M,
    3. Karrasch M,
    4. Boehm E,
    5. Polonski L,
    6. Ponikowski P &
    7. Rhein S

    2007 A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clinical Science 113 205–212doi:10.1042/CS20060307.
53. ↵
    1. Hudes G,
    2. Carducci M,
    3. Tomczak P,
    4. Dutcher J,
    5. Figlin R,
    6. Kapoor A,
    7. Staroslawska E,
    8. Sosman J,
    9. McDermott D,
    10. Bodrogi I
    11. et al.

    2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 356 2271–2281doi:10.1056/NEJMoa066838.
54. ↵
    1. Hwang PM,
    2. Bunz F,
    3. Yu J,
    4. Rago C,
    5. Chan TA,
    6. Murphy MP,
    7. Kelso GF,
    8. Smith RA,
    9. Kinzler KW &
    10. Vogelstein B

    2001 Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nature Medicine 7 1111–1117doi:10.1038/nm1001-1111.
55. ↵
    1. Inoki K,
    2. Zhu T &
    3. Guan KL

    2003 TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 577–590doi:10.1016/S0092-8674(03)00929-2.
56. ↵
    1. Ivan M,
    2. Haberberger T,
    3. Gervasi DC,
    4. Michelson KS,
    5. Gunzler V,
    6. Kondo K,
    7. Yang H,
    8. Sorokina I,
    9. Conaway RC,
    10. Conaway JW
    11. et al.

    2002 Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. PNAS 99 13459–13464doi:10.1073/pnas.192342099.
57. ↵
    1. Jin W,
    2. McCutcheon IE,
    3. Fuller GN,
    4. Huang ES &
    5. Cote GJ

    2000 Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. Cancer Research 60 1221–1224.
58. ↵
    1. Jones RG,
    2. Plas DR,
    3. Kubek S,
    4. Buzzai M,
    5. Mu J,
    6. Xu Y,
    7. Birnbaum MJ &
    8. Thompson CB

    2005 AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Molecular Cell 18 283–293doi:10.1016/j.molcel.2005.03.027.
59. ↵
    1. Khatri S,
    2. Yepiskoposyan H,
    3. Gallo CA,
    4. Tandon P &
    5. Plas DR

    2010 FOXO3a regulates glycolysis via transcriptional control of tumor suppressor TSC1. Journal of Biological Chemistry 285 15960–15965doi:10.1074/jbc.M110.121871.
60. ↵
    1. Kitevska T,
    2. Spencer DM &
    3. Hawkins CJ

    2009 Caspase-2: controversial killer or checkpoint controller? Apoptosis 14 829–848doi:10.1007/s10495-009-0365-3.
61. ↵
    1. Knowles MA,
    2. Habuchi T,
    3. Kennedy W &
    4. Cuthbert-Heavens D

    2003 Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Research 63 7652–7656.
62. ↵
    1. Knox WE,
    2. Horowitz ML &
    3. Friedell GH

    1969 The proportionality of glutaminase content to growth rate and morphology of rat neoplasms. Cancer Research 29 669–680.
63. ↵
    1. Kuhajda FP

    2000 Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16 202–208doi:10.1016/S0899-9007(99)00266-X.
64. ↵
    1. Kuhajda FP,
    2. Piantadosi S &
    3. Pasternack GR

    1989 Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. New England Journal of Medicine 321 636–641doi:10.1056/NEJM198909073211003.
65. ↵
    1. Kumar-Sinha C,
    2. Ignatoski KW,
    3. Lippman ME,
    4. Ethier SP &
    5. Chinnaiyan AM

    2003 Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Research 63 132–139.
66. ↵
    1. Lamia KA,
    2. Storch KF &
    3. Weitz CJ

    2008 Physiological significance of a peripheral tissue circadian clock. PNAS 105 15172–15177doi:10.1073/pnas.0806717105.
67. ↵
    1. Lamia KA,
    2. Sachdeva UM,
    3. DiTacchio L,
    4. Williams EC,
    5. Alvarez JG,
    6. Egan DF,
    7. Vasquez DS,
    8. Juguilon H,
    9. Panda S,
    10. Shaw RJ
    11. et al.

    2009 AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science 326 437–440doi:10.1126/science.1172156.
68. ↵
    1. Lehtonen R,
    2. Kiuru M,
    3. Vanharanta S,
    4. Sjoberg J,
    5. Aaltonen LM,
    6. Aittomaki K,
    7. Arola J,
    8. Butzow R,
    9. Eng C,
    10. Husgafvel-Pursiainen K
    11. et al.

    2004 Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. American Journal of Pathology 164 17–22.
69. ↵
    1. Li F,
    2. Wang Y,
    3. Zeller KI,
    4. Potter JJ,
    5. Wonsey DR,
    6. O'Donnell KA,
    7. Kim JW,
    8. Yustein JT,
    9. Lee LA &
    10. Dang CV

    2005 Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Molecular and Cellular Biology 25 6225–6234doi:10.1128/MCB.25.14.6225-6234.2005.
70. ↵
    1. Liu P,
    2. Cheng H,
    3. Roberts TM &
    4. Zhao JJ

    2009 Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews. Drug Discovery 8 627–644doi:10.1038/nrd2926.
71. ↵
    1. Lum JJ,
    2. Bauer DE,
    3. Kong M,
    4. Harris MH,
    5. Li C,
    6. Lindsten T &
    7. Thompson CB

    2005 Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120 237–248doi:10.1016/j.cell.2004.11.046.
72. ↵
    1. Marcucci G,
    2. Maharry K,
    3. Wu YZ,
    4. Radmacher MD,
    5. Mrozek K,
    6. Margeson D,
    7. Holland KB,
    8. Whitman SP,
    9. Becker H,
    10. Schwind S
    11. et al.

    2010 IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology 28 2348–2355doi:10.1200/JCO.2009.27.3730.
73. ↵
    1. Mardis ER,
    2. Ding L,
    3. Dooling DJ,
    4. Larson DE,
    5. McLellan MD,
    6. Chen K,
    7. Koboldt DC,
    8. Fulton RS,
    9. Delehaunty KD,
    10. McGrath SD
    11. et al.

    2009 Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine 361 1058–1066doi:10.1056/NEJMoa0903840.
74. ↵
    1. Maschek G,
    2. Savaraj N,
    3. Priebe W,
    4. Braunschweiger P,
    5. Hamilton K,
    6. Tidmarsh GF,
    7. De Young LR &
    8. Lampidis TJ

    2004 2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Research 64 31–34doi:10.1158/0008-5472.CAN-03-3294.
75. ↵
    1. Matoba S,
    2. Kang JG,
    3. Patino WD,
    4. Wragg A,
    5. Boehm M,
    6. Gavrilova O,
    7. Hurley PJ,
    8. Bunz F &
    9. Hwang PM

    2006 p53 regulates mitochondrial respiration. Science 312 1650–1653doi:10.1126/science.1126863.
76. ↵
    1. Mazurek S,
    2. Boschek CB,
    3. Hugo F &
    4. Eigenbrodt E

    2005 Pyruvate kinase type M2 and its role in tumor growth and spreading. Seminars in Cancer Biology 15 300–308doi:10.1016/j.semcancer.2005.04.009.
77. ↵
    1. Medes G,
    2. Thomas A &
    3. Weinhouse S

    1953 Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Research 13 27–29.
78. ↵
    1. Menendez JA &
    2. Lupu R

    2007 Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Reviews. Cancer 7 763–777doi:10.1038/nrc2222.
79. ↵
    1. Menendez JA,
    2. Vellon L,
    3. Colomer R &
    4. Lupu R

    2005 Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. International Journal of Cancer 115 19–35doi:10.1002/ijc.20754.
80. ↵
    1. Michelakis ED,
    2. Sutendra G,
    3. Dromparis P,
    4. Webster L,
    5. Haromy A,
    6. Niven E,
    7. Maguire C,
    8. Gammer TL,
    9. Mackey JR,
    10. Fulton D
    11. et al.

    2010 Metabolic modulation of glioblastoma with dichloroacetate. Science Translational Medicine 2 31ra34doi:10.1126/scitranslmed.3000677.
81. ↵
    1. Migita T,
    2. Narita T,
    3. Nomura K,
    4. Miyagi E,
    5. Inazuka F,
    6. Matsuura M,
    7. Ushijima M,
    8. Mashima T,
    9. Seimiya H,
    10. Satoh Y
    11. et al.

    2008 ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Research 68 8547–8554doi:10.1158/0008-5472.CAN-08-1235.
82. ↵
    1. Motzer RJ,
    2. Escudier B,
    3. Oudard S,
    4. Hutson TE,
    5. Porta C,
    6. Bracarda S,
    7. Grunwald V,
    8. Thompson JA,
    9. Figlin RA,
    10. Hollaender N
    11. et al.

    2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 449–456doi:10.1016/S0140-6736(08)61039-9.
83. ↵
    1. Nomura DK,
    2. Long JZ,
    3. Niessen S,
    4. Hoover HS,
    5. Ng SW &
    6. Cravatt BF

    2010 Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140 49–61doi:10.1016/j.cell.2009.11.027.
84. ↵
    1. Nutt LK,
    2. Margolis SS,
    3. Jensen M,
    4. Herman CE,
    5. Dunphy WG,
    6. Rathmell JC &
    7. Kornbluth S

    2005 Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2. Cell 123 89–103doi:10.1016/j.cell.2005.07.032.
85. ↵
    1. Nutt LK,
    2. Buchakjian MR,
    3. Gan E,
    4. Darbandi R,
    5. Yoon SY,
    6. Wu JQ,
    7. Miyamoto YJ,
    8. Gibbons JA,
    9. Andersen JL,
    10. Freel CD
    11. et al.

    2009 Metabolic control of oocyte apoptosis mediated by 14-3-3zeta-regulated dephosphorylation of caspase-2. Developmental Cell 16 856–866doi:10.1016/j.devcel.2009.04.005.
86. ↵
    1. Obeid LM,
    2. Linardic CM,
    3. Karolak LA &
    4. Hannun YA

    1993 Programmed cell death induced by ceramide. Science 259 1769–1771doi:10.1126/science.8456305.
87. ↵
    1. Ookhtens M,
    2. Kannan R,
    3. Lyon I &
    4. Baker N

    1984 Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. American Journal of Physiology 247 R146–R153.
88. ↵
    1. O'Reilly KE,
    2. Rojo F,
    3. She QB,
    4. Solit D,
    5. Mills GB,
    6. Smith D,
    7. Lane H,
    8. Hofmann F,
    9. Hicklin DJ,
    10. Ludwig DL
    11. et al.

    2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500–1508doi:10.1158/0008-5472.CAN-05-2925.
89. ↵
    1. Osthus RC,
    2. Shim H,
    3. Kim S,
    4. Li Q,
    5. Reddy R,
    6. Mukherjee M,
    7. Xu Y,
    8. Wonsey D,
    9. Lee LA &
    10. Dang CV

    2000 Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. Journal of Biological Chemistry 275 21797–21800doi:10.1074/jbc.C000023200.
90. ↵
    1. Ozturk N,
    2. Lee JH,
    3. Gaddameedhi S &
    4. Sancar A

    2009 Loss of cryptochrome reduces cancer risk in p53 mutant mice. PNAS 106 2841–2846doi:10.1073/pnas.0813028106.
91. ↵
    1. Parsons DW,
    2. Jones S,
    3. Zhang X,
    4. Lin JC,
    5. Leary RJ,
    6. Angenendt P,
    7. Mankoo P,
    8. Carter H,
    9. Siu IM,
    10. Gallia GL
    11. et al.

    2008 An integrated genomic analysis of human glioblastoma multiforme. Science 321 1807–1812doi:10.1126/science.1164382.
92. ↵
    1. Pearce EL,
    2. Walsh MC,
    3. Cejas PJ,
    4. Harms GM,
    5. Shen H,
    6. Wang LS,
    7. Jones RG &
    8. Choi Y

    2009 Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460 103–107doi:10.1038/nature08097.
93. ↵
    1. Plas DR &
    2. Thomas G

    2009 Tubers and tumors: rapamycin therapy for benign and malignant tumors. Current Opinion in Cell Biology 21 230–236doi:10.1016/j.ceb.2008.12.013.
94. ↵
    1. Plas DR,
    2. Talapatra S,
    3. Edinger AL,
    4. Rathmell JC &
    5. Thompson CB

    2001 Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. Journal of Biological Chemistry 276 12041–12048doi:10.1074/jbc.M010551200.
95. ↵
    1. Pollard PJ,
    2. Briere JJ,
    3. Alam NA,
    4. Barwell J,
    5. Barclay E,
    6. Wortham NC,
    7. Hunt T,
    8. Mitchell M,
    9. Olpin S,
    10. Moat SJ
    11. et al.

    2005 Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Human Molecular Genetics 14 2231–2239doi:10.1093/hmg/ddi227.
96. ↵
    1. Robey RB &
    2. Hay N

    2009 Is Akt the "Warburg kinase"? – Akt-energy metabolism interactions and oncogenesis. Seminars in Cancer Biology 19 25–31doi:10.1016/j.semcancer.2008.11.010.
97. ↵
    1. Sahar S &
    2. Sassone-Corsi P

    2009 Metabolism and cancer: the circadian clock connection. Nature Reviews. Cancer 9 886–896doi:10.1038/nrc2747.
98. ↵
    1. Samudio I,
    2. Fiegl M,
    3. McQueen T,
    4. Clise-Dwyer K &
    5. Andreeff M

    2008 The Warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Research 68 5198–5205doi:10.1158/0008-5472.CAN-08-0555.
99. ↵
    1. Samudio I,
    2. Harmancey R,
    3. Fiegl M,
    4. Kantarjian H,
    5. Konopleva M,
    6. Korchin B,
    7. Kaluarachchi K,
    8. Bornmann W,
    9. Duvvuri S,
    10. Taegtmeyer H
    11. et al.

    2010 Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. Journal of Clinical Investigation 120 142–156doi:10.1172/JCI38942.
100. ↵
     1. Sato T,
     2. Nakashima A,
     3. Guo L,
     4. Coffman K &
     5. Tamanoi F

     2010 Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29 2746–2752doi:10.1038/onc.2010.28.
101. ↵
     1. Schafer ZT,
     2. Grassian AR,
     3. Song L,
     4. Jiang Z,
     5. Gerhart-Hines Z,
     6. Irie HY,
     7. Gao S,
     8. Puigserver P &
     9. Brugge JS

     2009 Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461 109–113doi:10.1038/nature08268.
102. ↵
     1. Schernhammer ES,
     2. Kroenke CH,
     3. Laden F &
     4. Hankinson SE

     2006 Night work and risk of breast cancer. Epidemiology 17 108–111doi:10.1097/01.ede.0000190539.03500.c1.
103. ↵
     1. Schmidt-Schweda S &
     2. Holubarsch C

     2000 First clinical trial with etomoxir in patients with chronic congestive heart failure. Clinical Science 99 27–35doi:10.1042/CS19990235.
104. ↵
     1. Selak MA,
     2. Armour SM,
     3. MacKenzie ED,
     4. Boulahbel H,
     5. Watson DG,
     6. Mansfield KD,
     7. Pan Y,
     8. Simon MC,
     9. Thompson CB &
     10. Gottlieb E

     2005 Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7 77–85doi:10.1016/j.ccr.2004.11.022.
105. ↵
     1. Shurbaji MS,
     2. Kalbfleisch JH &
     3. Thurmond TS

     1996 Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Human Pathology 27 917–921doi:10.1016/S0046-8177(96)90218-X.
106. ↵
     1. Sidi S,
     2. Sanda T,
     3. Kennedy RD,
     4. Hagen AT,
     5. Jette CA,
     6. Hoffmans R,
     7. Pascual J,
     8. Imamura S,
     9. Kishi S,
     10. Amatruda JF
     11. et al.

     2008 Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133 864–877doi:10.1016/j.cell.2008.03.037.
107. ↵
     1. Sudarshan S,
     2. Sourbier C,
     3. Kong HS,
     4. Block K,
     5. Valera Romero VA,
     6. Yang Y,
     7. Galindo C,
     8. Mollapour M,
     9. Scroggins B,
     10. Goode N
     11. et al.

     2009 Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Molecular and Cellular Biology 29 4080–4090doi:10.1128/MCB.00483-09.
108. ↵
     1. Swinnen JV,
     2. Heemers H,
     3. Deboel L,
     4. Foufelle F,
     5. Heyns W &
     6. Verhoeven G

     2000 Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19 5173–5181doi:10.1038/sj.onc.1203889.
109. ↵
     1. Takahashi JS,
     2. Hong HK,
     3. Ko CH &
     4. McDearmon EL

     2008 The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nature Reviews. Genetics 9 764–775doi:10.1038/nrg2430.
110. ↵
     1. Toyokuni S,
     2. Okamoto K,
     3. Yodoi J &
     4. Hiai H

     1995 Persistent oxidative stress in cancer. FEBS Letters 358 1–3doi:10.1016/0014-5793(94)01368-B.
111. ↵
     1. Tu BP,
     2. Kudlicki A,
     3. Rowicka M &
     4. McKnight SL

     2005 Logic of the yeast metabolic cycle: temporal compartmentalization of cellular processes. Science 310 1152–1158doi:10.1126/science.1120499.
112. ↵
     1. Van de Sande T,
     2. De Schrijver E,
     3. Heyns W,
     4. Verhoeven G &
     5. Swinnen JV

     2002 Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Research 62 642–646.
113. ↵
     1. Vaughn AE &
     2. Deshmukh M

     2008 Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nature Cell Biology 10 1477–1483doi:10.1038/ncb1807.
114. ↵
     1. Wallace DC

     2005 A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annual Review of Genetics 39 359–407doi:10.1146/annurev.genet.39.110304.095751.
115. ↵
     1. Wan J,
     2. Jiang L,
     3. Lu Q,
     4. Ke L,
     5. Li X &
     6. Tong N

     2010 Activation of PPARdelta up-regulates fatty acid oxidation and energy uncoupling genes of mitochondria and reduces palmitate-induced apoptosis in pancreatic beta-cells. Biochemical and Biophysical Research Communications 391 1567–1572doi:10.1016/j.bbrc.2009.12.127.
116. ↵
     1. Wang GL,
     2. Jiang BH,
     3. Rue EA &
     4. Semenza GL

     1995 Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. PNAS 92 5510–5514doi:10.1073/pnas.92.12.5510.
117. ↵
     1. Wang C,
     2. Norton JT,
     3. Ghosh S,
     4. Kim J,
     5. Fushimi K,
     6. Wu JY,
     7. Stack MS &
     8. Huang S

     2008 Polypyrimidine tract-binding protein (PTB) differentially affects malignancy in a cell line-dependent manner. Journal of Biological Chemistry 283 20277–20287doi:10.1074/jbc.M803682200.
118. ↵
     1. Warburg O

     1. Warburg O,
     2. Posener K &
     3. Negelein E

     1931 VIII. The metabolism of the carcinoma cell. In The Metabolism of Tumours, pp 129–169 Ed. Warburg O. New York: Richard R. Smith, Inc.
119. ↵
     1. Ward PS,
     2. Patel J,
     3. Wise DR,
     4. Abdel-Wahab O,
     5. Bennett BD,
     6. Coller HA,
     7. Cross JR,
     8. Fantin VR,
     9. Hedvat CV,
     10. Perl AE
     11. et al.

     2010 The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17 225–234doi:10.1016/j.ccr.2010.01.020.
120. ↵
     1. Wise DR,
     2. DeBerardinis RJ,
     3. Mancuso A,
     4. Sayed N,
     5. Zhang XY,
     6. Pfeiffer HK,
     7. Nissim I,
     8. Daikhin E,
     9. Yudkoff M,
     10. McMahon SB
     11. et al.

     2008 Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. PNAS 105 18782–18787doi:10.1073/pnas.0810199105.
121. ↵
     1. Wolpin BM,
     2. Hezel AF,
     3. Abrams T,
     4. Blaszkowsky LS,
     5. Meyerhardt JA,
     6. Chan JA,
     7. Enzinger PC,
     8. Allen B,
     9. Clark JW,
     10. Ryan DP
     11. et al.

     2009 Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. Journal of Clinical Oncology 27 193–198doi:10.1200/JCO.2008.18.9514.
122. ↵
     1. Yang YA,
     2. Han WF,
     3. Morin PJ,
     4. Chrest FJ &
     5. Pizer ES

     2002 Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Experimental Cell Research 279 80–90doi:10.1006/excr.2002.5600.
123. ↵
     1. Yang C,
     2. Sudderth J,
     3. Dang T,
     4. Bachoo RM,
     5. McDonald JG &
     6. DeBerardinis RJ

     2009 Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Research 69 7986–7993doi:10.1158/0008-5472.CAN-09-2266.
124. ↵
     1. Yoon S,
     2. Lee MY,
     3. Park SW,
     4. Moon JS,
     5. Koh YK,
     6. Ahn YH,
     7. Park BW &
     8. Kim KS

     2007 Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. Journal of Biological Chemistry 282 26122–26131doi:10.1074/jbc.M702854200.
125. ↵
     1. Yu K,
     2. Shi C,
     3. Toral-Barza L,
     4. Lucas J,
     5. Shor B,
     6. Kim JE,
     7. Zhang WG,
     8. Mahoney R,
     9. Gaydos C,
     10. Tardio L
     11. et al.

     2010 Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Research 70 621–631doi:10.1158/0008-5472.CAN-09-2340.
126. ↵
     1. Yun J,
     2. Rago C,
     3. Cheong I,
     4. Pagliarini R,
     5. Angenendt P,
     6. Rajagopalan H,
     7. Schmidt K,
     8. Willson JK,
     9. Markowitz S,
     10. Zhou S
     11. et al.

     2009 Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325 1555–1559doi:10.1126/science.1174229.
127. ↵
     1. Yuneva M,
     2. Zamboni N,
     3. Oefner P,
     4. Sachidanandam R &
     5. Lazebnik Y

     2007 Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. Journal of Cell Biology 178 93–105doi:10.1083/jcb.200703099.
128. ↵
     1. Zhao S,
     2. Lin Y,
     3. Xu W,
     4. Jiang W,
     5. Zha Z,
     6. Wang P,
     7. Yu W,
     8. Li Z,
     9. Gong L,
     10. Peng Y
     11. et al.

     2009 Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324 261–265doi:10.1126/science.1170944.
129. ↵
     1. Zhou G,
     2. Myers R,
     3. Li Y,
     4. Chen Y,
     5. Shen X,
     6. Fenyk-Melody J,
     7. Wu M,
     8. Ventre J,
     9. Doebber T,
     10. Fujii N
     11. et al.

     2001 Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation 108 1167–1174doi:10.1172/JCI13505.